单克隆抗体应对最终药物的生产,配制,递送和稳定性方面的挑战 407条(本栏目收费,不能显示细节,电话13136136841)
silicone oil interactions with proteins and mAbs,155,156 156
viscous solutions delivery using,153,154 154
Primary structure,68,69 69
Protein aggregation,70,71 71
degradation routes in silico methods to assessing,105 105
mutants as result of performing mutations,184 184
free thiol generation,61 61
and mixed disulfides in mAbs,60,62 62
acid and base catalysis of,47 47
and Asp isomerization in mAbs,50,51 51
acid base mechanism,48,49 49
cyclic imide formation,49 49
X-ray crystal structure for mAb I Fab,49,50 50
Degradation routes in mAbs,45 45
chemical and physical protein degradation,46 46
chemical degradation,45,51 51
Delivery device technology development using delivery devices to deliver large volume mAb formulations,153 153
drug formulation in chloride-based formulations,158 158
injectors for SC delivery,155 155
interactions with stainless steel needles,157,159 159
filling of highly concentrated mAbs into,160 160
leachables impact from,157 157
problems with tungsten,159 159